利图西马布治疗与类风湿性关节炎相关的间歇性肺病:系统性审查和元分析
Tarun Krishna Boppana1, Saurabh Mittal1, Karan Madan1
1All India Institute of Medical Sciences, Pulmonary, Critical Care and Sleep Medicine, Delhi, India.
Archives of rheumatology
|June 27, 2024
概括
利图西马布在治疗类风湿性关节炎相关的间歇性肺病 (RA-ILD) 中显示出显著的疗效. 它稳定或改善肺部疾病,增强肺部强迫生命能力 (FVC) 和肺部对一氧化碳 (DLCO) 的扩散能力.
科学领域:
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 类风湿性关节炎相关的间歇性肺病 (RA-ILD) 是类风湿性关节炎的一个严重并发症.
- 目前对RA-ILD的治疗选择具有不同程度的疗效和安全性.
- 一种B细胞耗尽剂Rituximab已经成为RA-ILD的潜在治疗选择.
研究的目的:
- 系统地审查和分析关于利图西马布在RA-ILD患者的疗效和安全性的现有证据.
- 评估利图西马布对肺功能参数的影响,包括强迫生命能力 (FVC) 和肺部对一氧化碳 (DLCO) 的扩散能力.
- 评估与Rituximab治疗的患者间歇性肺病 (ILD) 的整体稳定或改善率.
主要方法:
- 在PubMed和Embase数据库中进行了全面的文献搜索,截至2022年6月22日.
- 涉及Rituximab治疗的RA-ILD的研究被确定并根据预定义的包含和排除标准进行选.
- 进行了系统性审查和元分析,以综合有关ILD稳定/改善的数据,%预测的FVC和%预测的DLCO的变化以及死亡率的数据.
主要成果:
- 包括15项研究 (4项前性,11项后性) 涉及314名患者.
- 总的ILD稳定或改善的患者比例为88% (95%CI:0.76-0.96).
- 利图西马布显著改善了%预测的FVC7.50% (p=0.02) 和%预测的DLCO6.39% (p=0.12). 两项研究表明,与TNF-α抑制剂相比,Rituximab可降低死亡率.
结论:
- 利图西马布治疗与RA-ILD患者的%预测FVC的显著改善有关.
- 利图西马布在稳定或改善RA患者间歇性肺病方面表现出有效性.
- 这些发现支持使用Rituximab作为治疗RA-ILD的治疗选择.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
402
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
402
01:27Pneumothorax-II
139
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
139
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130